Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response to Neoadjuvant Chemotherapy

Overview

Journal Eur J Breast Health

Publisher Galenos Publishing House

Date 2021 Apr 19

PMID 33870112

Citations 5

Authors

Hongxia Sun

Hui Chen

James Crespo

Guilin Tang

Melissa Robinson

Bora Lim

Aysegul A Sahin

Affiliations

Soon will be listed here.

Abstract

Objective: The interpretation of human epidermal growth factor receptor 2 () fluorescence in situ hybridization (FISH) results may be challenging in tumors with polysomy 17, which is defined as increased signals of chromosome enumeration probe 17 (CEP17). The effect of polysomy 17 on protein expression and tumor treatment response has not been established. In this retrospective study, we investigated the clinicopathological features of breast cancer with polysomy 17 and determined the tumors' response to neoadjuvant chemotherapy (NACT).

Materials And Methods: The study included 366 patients with primary breast cancer whose tumors had a CEP17 count of ≥ three/nucleus based on FISH studies. These cases were categorized according to /CEP17 ratio and signals/nucleus using the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines. We compared the clinicopathological characteristics and tumor response to NACT among different groups.

Results: There was a statistically significant difference in patients' age at diagnosis, tumor pathological grade, estrogen and progesterone receptor status, and NACT response among different FISH groups. Polysomy 17 tumors in group 1 had a higher rate of response (pathological complete response and residual cancer burden class I) to NACT containing anti- reagent than did those in other groups (p = 0.004), whereas polysomy 17 tumors in group 3 did not show a significant response to anti- treatment.

Conclusion: Polysomy 17 tumors in different FISH groups have different pathological features and respond to NACT differently. These results may help us identify patients who will benefit from anti- therapy.

Citing Articles

In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment.

Lien H, Lo C, Lee Y, Lin P, Wang M, Kuo W Breast Cancer Res. 2024; 26(1):100.

PMID: 38867307 PMC: 11170871. DOI: 10.1186/s13058-024-01852-3.

HER2 copy number determination in breast cancer using the highly sensitive droplet digital PCR method.

Alinger-Scharinger B, Kronberger C, Hutarew G, Hitzl W, Reitsamer R, Frederike K Virchows Arch. 2023; 485(1):53-62.

PMID: 37996704 PMC: 11271376. DOI: 10.1007/s00428-023-03706-3.

Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.

Ivanova M, Porta F, DErcole M, Pescia C, Sajjadi E, Cursano G Virchows Arch. 2023; 484(1):3-14.

PMID: 37770765 PMC: 10791807. DOI: 10.1007/s00428-023-03656-w.

HER2 Amplification in p53-Mutated Endometrial Carcinomas.

Balestra A, Larsimont D, Noel J Cancers (Basel). 2023; 15(5).

PMID: 36900227 PMC: 10001224. DOI: 10.3390/cancers15051435.

Validation of HER2 Status in Whole Genome Sequencing Data of Breast Cancers with the Ploidy-Corrected Copy Number Approach.

Wojtaszewska M, Stepien R, Wozna A, Piernik M, Sztromwasser P, Dabrowski M Mol Diagn Ther. 2021; 26(1):105-116.

PMID: 34932189 PMC: 8766398. DOI: 10.1007/s40291-021-00571-1.

References

Sneige N, Hess K, Multani A, Gong Y, Ibrahim N . Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. Cancer. 2016; 123(7):1115-1123. PMC: 5372352. DOI: 10.1002/cncr.30460. View

Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens M . Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol. 2008; 26(30):4869-74. DOI: 10.1200/JCO.2007.13.4296. View

Wolff A, Hammond M, Allison K, Harvey B, Mangu P, Bartlett J . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 36(20):2105-2122. DOI: 10.1200/JCO.2018.77.8738. View

Petroni S, Addati T, Mattioli E, Caponio M, Quero C, Rubini V . Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?. Arch Pathol Lab Med. 2012; 136(9):993-1000. DOI: 10.5858/arpa.2011-0327-OA. View

Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L . Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3):719-26. DOI: 10.1200/JCO.2002.20.3.719. View

Joensuu H, Kellokumpu-Lehtinen P, Bono P, Alanko T, Kataja V, Asola R . Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354(8):809-20. DOI: 10.1056/NEJMoa053028. View

Takehisa M, Sasa M, Bando Y, Hirose T, Morimoto T, Nagao T . Chromosomal aneusomy (chr 1, 11, 17) detected by fluorescence in situ hybridization may be a prognostic factor in breast cancer. Anticancer Res. 2007; 27(2):1073-8. View

Varshney D, Zhou Y, Geller S, Alsabeh R . Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol. 2004; 121(1):70-7. DOI: 10.1309/FUQH-92B0-3902-5LHG. View

Downs-Kelly E, Yoder B, Stoler M, Tubbs R, Skacel M, Grogan T . The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 2005; 29(9):1221-7. DOI: 10.1097/01.pas.0000165528.78945.95. View

10.

Torrisi R, Rotmensz N, Bagnardi V, Viale G, Del Curto B, DellOrto P . HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer. 2007; 43(16):2339-44. DOI: 10.1016/j.ejca.2007.07.033. View

11.

Hyun C, Lee H, Kim K, Kim S, Kim J, Choe G . The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol. 2007; 61(3):317-21. DOI: 10.1136/jcp.2007.050336. View

12.

Marchio C, Lambros M, Gugliotta P, Verdun di Cantogno L, Botta C, Pasini B . Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol. 2009; 219(1):16-24. DOI: 10.1002/path.2574. View

13.

Lal P, Salazar P, Ladanyi M, Chen B . Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn. 2003; 5(3):155-9. PMC: 1907330. DOI: 10.1016/S1525-1578(10)60467-9. View

14.

Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-Galdon M . Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res. 2005; 11(12):4393-9. DOI: 10.1158/1078-0432.CCR-04-2256. View

15.

Popescu N, King C, Kraus M . Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics. 1989; 4(3):362-6. DOI: 10.1016/0888-7543(89)90343-1. View

16.

Downey L, Livingston R, Koehler M, Arbushites M, Williams L, Santiago A . Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin Cancer Res. 2010; 16(4):1281-8. DOI: 10.1158/1078-0432.CCR-09-1643. View

17.

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997-4013. DOI: 10.1200/JCO.2013.50.9984. View

18.

Agersborg S, Mixon C, Nguyen T, Aithal S, Sudarsanam S, Blocker F . Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification. Breast Cancer Res Treat. 2018; 170(2):321-328. PMC: 5999182. DOI: 10.1007/s10549-018-4755-5. View

19.

Salido M, Tusquets I, Corominas J, Suarez M, Espinet B, Corzo C . Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res. 2005; 7(2):R267-73. PMC: 1064140. DOI: 10.1186/bcr996. View

20.

Kallioniemi O, Holli K, Visakorpi T, Koivula T, Helin H, Isola J . Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991; 49(5):650-5. DOI: 10.1002/ijc.2910490504. View